Immunic Highlights Vidofludimus Calcium's Progress at ECTRIMS Congress

Immunic, Inc. showcased promising data at the 41st Congress of ECTRIMS on vidofludimus calcium, emphasizing its potential in multiple sclerosis (MS). The drug showed significant improvement in 24-week confirmed disability in the phase 2 CALLIPER trial targeting progressive MS. This data suggests neuroprotective potential and indicates a reduction in disability progression, particularly in patients without focal inflammation.

Additionally, long-term data from the EMPhASIS trial in relapsing-remitting MS also demonstrated high patient retention without disability worsening, supporting its favorable safety profile. Vidofludimus calcium's innovative mechanism, as a Nurr1 activator, offers novel pathways for preventing neurodegeneration. Immunic aims to advance this compound into further clinical trials to solidify its role in MS treatment.